Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Contribution of factor H-Binding protein sequence to the cross-reactivity of meningococcal native outer membrane vesicle vaccines with over-expressed fHbp variant group 1.

Marini A, Rossi O, Aruta MG, Micoli F, Rondini S, Guadagnuolo S, Delany I, Henderson IR, Cunningham AF, Saul A, MacLennan CA, Koeberling O.

PLoS One. 2017 Jul 25;12(7):e0181508. doi: 10.1371/journal.pone.0181508. eCollection 2017.

2.

Comparison of colorimetric assays with quantitative amino acid analysis for protein quantification of Generalized Modules for Membrane Antigens (GMMA).

Rossi O, Maggiore L, Necchi F, Koeberling O, MacLennan CA, Saul A, Gerke C.

Mol Biotechnol. 2015 Jan;57(1):84-93. doi: 10.1007/s12033-014-9804-7.

3.

A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA).

Koeberling O, Ispasanie E, Hauser J, Rossi O, Pluschke G, Caugant DA, Saul A, MacLennan CA.

Vaccine. 2014 May 13;32(23):2688-95. doi: 10.1016/j.vaccine.2014.03.068. Epub 2014 Apr 3.

4.

Characterization of vaccine antigens of meningococcal serogroup W isolates from Ghana and Burkina Faso from 2003 to 2009.

Ispasanie E, Pluschke G, Hodgson A, Sie A, MacLennan C, Koeberling O.

F1000Res. 2014 Nov 3;3:264. doi: 10.12688/f1000research.3881.1. eCollection 2014.

5.

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.

Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1302. doi: 10.1371/journal.pntd.0001302. Epub 2011 Sep 6.

6.

Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.

Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, Donnelly J, Granoff DM.

Vaccine. 2011 Jun 24;29(29-30):4728-34. doi: 10.1016/j.vaccine.2011.04.095. Epub 2011 May 13.

7.
8.

Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa.

Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM.

J Infect Dis. 2009 May 1;199(9):1360-8. doi: 10.1086/597806.

9.

Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2.

Koeberling O, Giuntini S, Seubert A, Granoff DM.

Clin Vaccine Immunol. 2009 Feb;16(2):156-62. doi: 10.1128/CVI.00403-08. Epub 2008 Dec 24.

10.

Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein.

Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, Granoff DM.

Infect Immun. 2008 Sep;76(9):4232-40. doi: 10.1128/IAI.00367-08. Epub 2008 Jun 30.

11.
12.

Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen.

Welsch JA, Ram S, Koeberling O, Granoff DM.

J Infect Dis. 2008 Apr 1;197(7):1053-61. doi: 10.1086/528994.

PMID:
18419542
13.

Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870.

Koeberling O, Welsch JA, Granoff DM.

Vaccine. 2007 Feb 26;25(10):1912-20. Epub 2006 Apr 21.

PMID:
16677743
14.

Supplemental Content

Loading ...
Support Center